Subcutaneous vedolizumab ‘effective for maintenance’ in Crohn’s disease
Patients responsive to the IV formulation may find subcutaneous dosing more convenient, expert says
Subcutaneous vedolizumab appears to be an effective and safe maintenance therapy for responsive patients with moderate to severe active Crohn’s disease, clinical trial results show.
The VISIBLE-2 double-blinded phase III trial, funded by the manufacturer of vedolizumab, Takeda, enrolled adults who had moderate to severe active Crohn’s disease for least three months at 169 sites in 30 countries.
The participants also had inadequate response to or intolerance of corticosteroids, immunomodulators or anti-tumour necrosis factor therapies.
More than 600 patients received two intravenous doses of open-label vedolizumab 300 mg at weeks 0 and 2.
